EGRF

AcronymDefinition
EGRFÉconomie et Gestion des Risques Financiers (French: Economics and Financial Risk Management)
References in periodicals archive ?
(22) Because some patients do not experience adverse effects with EGRF therapy agents, drugs and creams to combat toxicity can be initiated only after symptoms appear.
% OF WORLDWIDE ROAD DEATHS Population Vehicles % traffic Region Global % Global % deaths HMCs * 15 60 14 Asia/Pacific 54 16 44 Central/Eastern Europe 7 6 12 Latin America/Caribbean 8 14 13 Africa 11 4 11 Middle East/North Africa 4 2 6 * HMCs= Highly Motorised Countries (Canada, Japan, US, Western Europe) Sources: EGRF Factbook 2005; World Health Organisation; JAM Research.
(%) 134 (20.0) Triglyceride, 25.7-73.4 mg/dL 130.0 (90.3-177.9) Total cholesterol, 108.3-220.4 mg/dL 146.5 (119.5-175.9) HDL cholesterol, >34.8 mg/dL 71.1 (60.2-91.3) LDL cholesterol, <154.7 mg/dL 56.4 (32.1-73.9) Calcium concentration, 8.4-10.8 mg/dL 8.2 [+ or -] 1.3 Phosphate concentration, 2.5-4.5 mg/dL 5.3 (4.0-6.7) Serum albumin, 40-55 g/L 33.7 [+ or -] 7.8 Hs-cTnT, <14 ng/L 74.2 (38.9-133.9) Serum creatinine, 0.60-1.58 mg/dL 8.92 (6.73-11.64) eGRF, >90 mL [min.sup.-1] 5.75 (4.28-7.53) [(1.73 [m.sup.2]).sup.-1] Time undergoing dialysis, mo 26.7 (12.3-35.2) Follow-up mortality, No.
Renal function was presented by eGRF which was calculated by Modification of Diet in Renal Disease (MDRD) formula [14].
The eGRF (ml/min/ 1.73 [m.sup.2]) was calculated by MDRD formula when the patients were enrolled in the study.
In LAM-C arm, 33 patients were in stage II renal function and their eGRF was from baseline 74.0 [+ or -] 7.5 ml/min to 73.1 [+ or -] 9.2 ml/min at the end of one year (p = 0.471); 23 patients were in stage III renal function and their eGRF was from baseline 47.0 [+ or -] 8.8 ml/min to 49.0 [+ or -] 11.3 ml/min at the end of one year (p = 0.058).
For the 32 patients in stage II, eGRF was improved from baseline 74.7 [+ or -] 6.9 ml/min to 79.7 [+ or -] 8.7 ml/min at 10 months (p = 0.007) and 84.2 [+ or -] 16.6 ml/min at 12 months of LdT administration (p = 0.002).
This result implied that eGRF was continuously improved until 18 months after medication shifting.
The eGRF was improved by 3.6 to 15.3 ml/min in stage II patients and 7.1 to 15.8 ml/min in stage III patients.
Caption: Figure 3: The eGRF for the patients in the two arms.